Extremely low birth weight (ELBW) infants are at risk for hypotension. Abnormal adrenal function may play a role in the pathogenesis of hypotension, and therefore, the administration of hydrocortisone (HC) may be an effective treatment for hypotension in some infants. However, the efficacy of prophylactic HC to prevent the use of vasopressors for a defined hypotensive state has not been studied. We conducted a randomized-controlled trial to determine the potential role on adrenal insufficiency in early neonatal hypotension and to determine the effectiveness of prophylactic HC in reducing treatment of hypotension in ELBW infants.
INTRODUCTION
Hypotension is a frequent problem in extremely low birth weight (ELBW) infants. Estimates of the incidence of hypotension in this population range from 20 to 45%, and prevalence is inversely proportional to gestational age. 1, 2 Prolonged hypotension is associated with central nervous system morbidity and mortality in the neonate. 3, 4 Therapeutic interventions for the treatment of hypotension include the administration of intravenous fluid boluses and the use of vasopressors (VP), such as dopamine, dobutamine, and epinephrine. However, these therapies are not without risks. Fluid boluses increase the likelihood of persistent patency of the ductus arteriosus, and continuous infusions of VP may perturb perfusion to vital organs. 5 Alternatively, morbidity from ischemia may be exacerbated when hypotension is refractory to initial therapies.
The etiology of hypotension in low birth weight infants is likely multifactorial, but existing research suggests a link between adrenal cortical insufficiency and low blood pressure. [6] [7] [8] [9] Dexamethasone has been shown to increase blood pressure in neonates with hypotension unresponsive to intravenous fluid boluses and infusions of VP, possibly because it repletes cortisol in adrenal insufficient patients. [10] [11] [12] However, treatment with dexamethasone has been associated with adverse outcomes, including developmental delay, 13 small bowel perforations, 14 and infectious complications. 15 Therefore, its routine use is not recommended. Recent studies suggest that hydrocortisone (HC) may be a safer alternative to dexamethasone for the treatment of refractory hypotension in the preterm infant. 6, [16] [17] [18] The purpose of this pilot study was to further clarify the role of adrenal insufficiency in the pathogenesis of hypotension in ELBW infants, and to determine if early replacement therapy would improve blood pressure, thereby, reducing the need for vasopressor therapy in this population.
METHODS Population
This was a randomized, double-blinded, placebo-controlled trial. Subjects were admitted to the Newborn Critical Care Center at the North Carolina Children's Hospital between May 2000 and May 2002. Eligibility criteria included: inborn patients with gestational age >23 weeks and <29 weeks, and birth weight >500 and <1000 g. Exclusion criteria included: major malformations, chromosomal abnormalities, and congenital heart disease. All infants were screened for eligibility and enrollment was initiated by 2 hours of age. The institutional review board of the University of North Carolina School of Medicine approved the study. Parental consent was obtained prior to delivery.
Procedures
Infants were randomly assigned to hydrocortisone (HC group) or placebo treatment groups. Infants were randomized using sequentially numbered, preassigned treatment designations in sealed, opaque envelopes. Owing to the small sample size and the desire for homogenous cohorts, infants of multiple gestations were randomized as separate subjects. HC and placebo doses were prepared by the hospital investigational pharmacy. Infants assigned to the HC group received intravenous HC (Solu-Cortef s ) at a dose of 1 mg/kg every 12 hours for 2 days (B20 mg/m 2 /day), followed by a dose of 0.3 mg/kg every 12 hours for 3 days. These doses estimate stress and physiologic doses, respectively. 19 The placebo was normal saline given as an equivalent volume. Clinicians were blinded to treatment identity.
Due to variations in practice, nonspecific clinical signs, and poorly defined normative arterial pressures in ELBW infants, hypotension was defined as an abnormally low mean arterial pressure based on an adaptation of the standards for normal ranges published by Kitterman et al. 20 and Versmold et al. 21 Specifically, hypotension was defined as mean arterial pressure less than 24 mmHg for infants <750 g and less than 25 mmHg for infants 750 to 1000 g. All patients were treated with a standardized algorithm for hypotension. Until hypotension resolved, infants were treated sequentially with the following therapies: (1) up to two fluid boluses of lactated ringers solution (10 ml/kg), (2) dopamine, (3) dobutamine (both increased to a maximum dose of 20 mg/kg/ minute), and (4) epinephrine (increased to a maximum dose of 1 mg/kg/minute). If hypotension persisted, the subject's randomization assignment could be unblinded and HC administered, if the patient had been assigned to the placebo group.
Data Collection
Data abstracted from the medical record included maternal and patient demographics, delivery history, laboratory and clinical data, and outcomes to discharge. A Clinical Risk Index for Babies (CRIB) score was calculated at 12 hours of age to categorize each infant's severity of illness. 22 Blood pressure values, the use of fluid boluses, 23 Periventricular echo lucencies were assessed by blinded pediatric radiologists as part of routine ELBW infant care. 24 Serum cortisol levels were obtained before study drug administration, and again at 7 and 14 days of age. As preterm infants do not secrete cortisol in circadian cycles, 25 levels were obtained on these days at times when other blood specimens were drawn. The blood specimens for cortisol levels were collected in serum separator tubes without additives. Levels were measured by competitive immunoassay on a Vitros EC1 s machine. Values are expressed as micrograms/deciliter (mg/dl). Levels greater than 61.5 mg/dl were confirmed by dilution methods.
Data Analysis
The primary outcome variable was (the prospectively determined need for) treatment of hypotension with VP indicating a blood pressure below either 24 or 25 mmHg, dependent upon birth weight. Secondary end points were days on VP and maximum dose (mg/kg/minute) administered. Additional outcomes included cortisol levels and those listed as adverse above.
Baseline characteristics, adverse outcomes, and VP use by day were compared between groups with Student's t-tests, w 2 -tests, or their nonparametric equivalents, Fisher's exact and Wilcoxon's rank sum tests, as appropriate. A linear mixed-effects model was used to examine cortisol levels as a function of day post-treatment.
The sample size was estimated on the basis of a clinically important difference of 30% in mean VP use between groups. Based on a chart review performed at our institution prior to the study, it was determined that the incidence of VP-treated hypotension in ELBW infants was approximately 50%. We estimated that 44 infants per group were necessary to obtain a power of 80% with an alpha of 0.05. Based on the average annual admission rate for ELBW infants at the institution, we anticipated enrolment to be completed within 18 months.
RESULTS

Population
Between May 2000 and May 2002, 111 infants meeting eligibility criteria were delivered at the North Carolina Children's Hospital.
The parents of 66 infants were approached for consent prior to delivery. The parents of 14 infants refused consent, five infants weighed >1000 g at birth and were therefore not eligible, and 13 infants were delivered before consent was obtained. A total of 34 infants were enrolled in the study. Based on the unexpectedly slow rate of enrolment, we elected to perform an interim analysis to determine if our sample size calculation was accurate. The interim analysis predicted that an additional 60 infants would have to be enrolled to conclude that treatment was efficacious. The decision to terminate the study at this time was based on two factors. Given the rate of enrolment, continuing to this sample size was deemed to be impractical. In addition, a national collaborative study investigating HC therapy used in a similar manner was underway. Our study was not sufficiently large to address questions regarding some adverse effects. Therefore, we did not feel that it was advisable to continue enrolment.
Baseline characteristics for the infants are shown in Table 1 . There were no significant differences between groups for any of the characteristics listed. The similarity of birth weights, gestational ages, and CRIB scores suggest that the groups had comparable severity of illness. The placebo group had a somewhat larger percentage of male infants. In all, 59% of infants were from multiple gestations. The only characteristic in which there was a large numerical difference between groups was prolonged rupture of membranes (>18 hours).
The average time to first treatment was 148±50 minutes in the HC group, and 141±63 minutes in the placebo group. Figure 1 shows VP use by day between groups. A total of 25% of the HC group received VP by 24 hours of age compared to 44% of the placebo group (p ¼ 0.24). On the second day of life, only 7% of the HC group received VP compared to 39% of the placebo group (p<0.05). All infants receiving VP on the second and third day of life had been treated with VP during the first day of life. No infant was treated with VP during the fourth day of life. One infant in the HC group required VP support following gastric perforation on the sixth day of life. One infant in the placebo group received VP on the fifth day of life during Pseudomonas sepsis.
Vasopressor Use
Among infants treated with VP, the average maximum dose of dopamine on the first day of life in the HC group was 9.3±4.3 mg/ kg/minute (range 5 to 15), compared to a dose of 11.2±4.1 mg/kg/ minute (range 6 to 15) in the placebo group (p ¼ 0.19). Three patients in the placebo group and no patients in the HC group received dobutamine. No patients received epinephrine for hypotension. There was no unblinding of subjects during the study. Table 2 lists the average cortisol levels by group. There was no significant difference in cortisol levels between groups at any time point (see #4) in the placebo group were less than 5 mg/dl, a level associated with adrenal insufficiency in ELBW infants. 26, 27 There was no relationship between cortisol levels at baseline and the presence or development of hypotension in either group. Among the eight infants in the HC group with low baseline cortisol levels, a similar number of infants received VP compared to the number receiving VP among infants in the HC group with normal baseline cortisol levels. 
Cortisol Levels
Adverse Outcomes
There were no significant differences in mortality, ventilator days, chronic lung disease (defined as need for oxygen at 36 weeks postmenstrual age), nosocomial infections, NEC, spontaneous intestinal perforations, or IVH (Table 3) . No patients were treated or removed from the study as a result of hypertension. There was no difference in the rate of glucose intolerance (defined as BS >250 mg/dl) between groups. However, two patients in the HC group received insulin for a total of 5 days. One infant in the HC group was diagnosed with gastric perforation in the first week of life. The mother of this infant was diagnosed with HELLP syndrome and received high-dose steroids for treatment of thrombocytopenia prior to delivery. No infants received postnatal steroids within the first 2 weeks of life. In the HC group there were two deaths due to respiratory failure. In the placebo group there were three deaths. Causes of these deaths included cardiac failure, renal failure, and pneumonia.
DISCUSSION
Hypotension is common among ELBW infants and is associated with serious morbidity. Therapies for the treatment of low blood pressure include blood volume expansion, treatment with sympathomimetic amines, and more recently steroid administration. Our results suggest that the prophylactic administration of HC at doses that mimic the normal production of cortisol following delivery decreases the need for VP support in some ELBW infants. We found that HC supplementation therapy reduced treatment with VP during the first 2 days of life. Our observation complements earlier reports that this therapy is an effective treatment of hypotension that is refractory to VP. 6, [16] [17] [18] The primary end point of this study, treatment with VP is based on an operational definition of hypotension and a care practice in response to this a priori definition. Both the definition and treatment of hypotension are controversial in ELBW infants, but we felt that this was the best available methodology at the time of study design. 28, 29 Since blood pressure is dependent upon gestational and postnatal age, 30, 31 defining normal blood pressure using distributions of values in populations is problematic. This is especially true when standards for all premature infants are applied to ELBW infants, because published studies generally include few infants at very early gestations and extremely low birth weights. Further, many infants in reference studies are not normal in the sense that they may have underlying pathology or are receiving therapies that might influence blood pressure. A normal blood pressure range for ELBW infants, based on a more meaningful variable such as organ blood flow, has not been established. 29 In this study, we minimized the potential impact of variable clinician decision making by using a standardized algorithm for diagnosing and treating hypotension. However, we do not claim that this operational definition necessarily defines a pathologic state in all infants.
Premature infants, particularly ELBW infants, are more likely to have adrenal insufficiency due to an immature hypothalamicpituitary-adrenal axis that is not capable of producing adequate levels of steroids. 8, 32, 33 An additional aim of this study was to gather further evidence for the role of adrenal function, specifically cortisol production, in the maintenance of blood pressure. Our findings do not provide direct evidence for this role, as there was no apparent relationship between baseline cortisol levels and the presence of hypotension. In addition, there was no greater likelihood of benefit from HC therapy among infants with lower baseline cortisol levels.
The lack of correlation between cortisol levels and hypotension in the neonate has been reported previously. Heckmann et al. 34 found a difference in cortisol levels between hypotensive and well preterm infants; however, the authors were unable to show any relationship between response to steroids and cortisol level among hypotensive infants. Bourchier et al. 35 concluded that basal cortisol levels did not predict success of treatment with HC. Other investigators have not observed a correlation between baseline cortisol levels and the development of chronic lung disease, 8, 36 and between severity of illness and cortisol levels. 9, 34 A limitation of the study, and therefore our ability to draw conclusions regarding the role of adrenal function in the maintenance of blood pressure, may have been the method used to detect adrenal insufficiency. Although a single random cortisol measurement provides some estimate of adrenal status in the low birth weight infant, 9,27,37 the ACTH stimulation test may have provided a more accurate assessment. It is also possible that HC has pharmacological effects that are independent of endogenous cortisol production or a deficiency state. For example, exogenous glucocorticoids upregulate adrenergic receptors thereby reversing pressor resistance. 38 We did not observe improvement in any short-term outcomes, nor did we observe any adverse effects resulting from treatment with HC. This study was a pilot trial designed to determine if there was a positive treatment effect and was not powered to identify modest differences in clinical outcomes, so it is not surprising that we did not identify trends towards adverse outcomes that have been identified in other studies of glucocorticoids. [39] [40] [41] [42] We did not see any trend toward an increasing number of intestinal perforations among the treated group as has been found in a recent multicenter trial by KL Watterberg et al. (public communication at Hot Topics, Washington, DC, 2003, entitled Prophylaxis of early adrenal insufficiency to prevent BPD: multicenter trial). One difference between patient populations may be the percentage of infants that received prophylactic indomethacin, since the combination of steroid and indomethacin prophylaxis is associated with a higher risk of intestinal perforations than steroids alone. 42 Only 12% of our study population received prophylactic indomethacin during the trial (Table 1) . We also observed comparable cortisol levels at 7 and 14 days of life between groups, suggesting that our regimen for HC supplementation did not cause adrenal cortical suppression.
This study had several important limitations. First, therapy was initiated as early as was practical after birth, but 10 infants (six in the treatment group and four in the placebo group) had already received treatment for hypotension (in the form of fluid boluses) at the time of randomization. Therefore, the study was not strictly an investigation of prophylactic treatment, but rather one of intention to treat. Owing to the requirement for antenatal consent, our sample had an inherent bias for selection of subjects that excluded infants delivered emergently. As a result, infants with the usual perinatal problems that provoke emergent delivery (e.g. placental abruption) were under-represented in this study. By contrast, the preferential inclusion of infants with a prolonged intrapartum period and multiple births resulted in an extremely homogenous cohort of infants (with siblings commonly enrolled in opposite treatment arms). While our patient population should probably not be extrapolated to ELBW infants born by precipitous delivery, the probability that our observed difference is due to our intended treatment is high.
Another study limitation is the high prevalence of antenatal steroid therapy in our patient population. Prenatal steroid exposure has been shown to cause rebound suppression of cortisol levels in the immediate postnatal period. 43, 44 Since all but one of the infants in our study received antenatal steroids; our ELBW population would be expected to have a fairly homogenous decline in cortisol availability during the first few days of life. This antenatal confounder was evenly distributed across both treatment cohorts and our results are consistent with the possibility that prophylactic HC supplementation may reduce the incidence of rebound adrenal suppression in the first days of life.
CONCLUSION
The prophylactic administration of HC to ELBW infants at doses that replicate physiologic levels around the time of birth reduces treatment with vasopressors for hypotension in the first 2 days of life based on a common and a priori protocol for the identification and treatment of hypotension. Although this study does not further clarify the precise role of adrenal function in the maintenance of blood pressure, these results suggest a role, and further, suggest that a cortisol replacement strategy may be beneficial. However, the mounting evidence that prophylactic administration of glucocorticoids in the first days of life is harmful to ELBW infants makes HC prophylaxis unwise until the efficacy of treatment relative to safety can be clearly established. Of particular interest will be how the combination of indomethacin and glucocorticoids affects adverse outcomes such as intestinal perforation.
